Mitek Systems (NASDAQ:MITK) Director Gerald I. Farmer sold 15,000 shares of Mitek Systems stock on the open market in a transaction dated Thursday, February 27th. The stock was sold at an average price of $5.12, for a total value of $76,800.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Mitek Systems, Inc. (NASDAQ:MITK) shares after opening at $4.16 moved to $4.22 on last trade day and at the end of the day closed at $3.75. Company price to sales ratio in past twelve months was calculated as 7.13 and price to cash ratio as 4.87. Mitek Systems, Inc. (NASDAQ:MITK) showed a negative weekly performance of -15.35%.
Ceres, Inc. (Nasdaq:CERE) announced the pricing of an underwritten public offering of 20,000,000 shares of common stock at a public offering price of $1.00 per share. Ceres also granted the underwriters a 45-day option to purchase up to 3,000,000 additional shares of common stock to cover over-allotments, if any. Ceres expects to receive approximately $20 million in gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by the company. Ceres intends to use the net proceeds from this offering for general corporate purposes, including working capital. Ceres Inc (NASDAQ:CERE) shares fell -4.96% in last trading session and ended the day on $0.860. CERE return on equity ratio is recorded as -111.20% and its return on assets is -18.10%. Ceres Inc (NASDAQ:CERE) yearly performance is -75.22%.
Ventrus Biosciences Inc (NASDAQ:VTUS)’s shares jumped 2.94% to $1.40. The company on Feb. 12 announced top line efficacy and safety results from the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related to anal fissure (AF). In this randomized double blind trial comparing diltiazem 2% cream versus placebo cream in 434 subjects in 90 centers globally, both treatment arms demonstrated a clinically meaningful improvement. The diltiazem 2% treatment arm demonstrated no significant improvement compared to placebo in the primary endpoint of average of worst anal pain associated with or following defecation. The mean of worst AF-related pain score at baseline was 7.09 for diltiazem 2% and 7.18 for placebo, decreasing to 3.81 (-3.28 difference) and 3.72 (-3.46 difference) respectively. Ventrus Biosciences Inc (NASDAQ:VTUS) shares moved down -3.62% in last trading session and was closed at $1.33, while trading in range of $1.31-$1.42. Ventrus Biosciences Inc (NASDAQ:VTUS) year to date performance is -65.18%.
CTC Media (NASDAQ:CTCM) was downgraded by research analysts at TheStreet from a “buy” rating to a “hold” rating in a report released on Wednesday, Analyst RN reports. CTC Media, Inc. (NASDAQ:CTCM) weekly performance is -7.00%. On last trading day company shares ended up $8.50. CTC Media, Inc. (NASDAQ:CTCM) distance from 50-day simple moving average (SMA50) is 757%. Analysts mean target price for the company is $12.17.